Highly regulated, with strict compliance rules, work can be in-house or in collaboration with another entity. Guidance includes practice notes on UK and EU regime for clinical trials and various precedents.
Patents and supplementary protection certificates are significant to many life sciences businesses. We have practice notes on pharmaceutical patents, biotechnology patents, IP protection for medical devices and more.
This content includes guidance on marketing authorisations, orphan and paediatric medicines, pharmacovigilance, manufacturing, unlicensed and off-label medicines.
Covering key areas of medical devices regulation including classification, conformity assessments, clinical and performance evaluation as well as post-market surveillance.
MedTech for Europe has published a joint statement by a coalition of technology providers, digital infrastructure companies, medical technology...
Medicines for Europe (MFE) and Medicines for Ireland (MFI) have welcomed a decision by the Irish High Court to refer questions to the Court of Justice...
The European Commission has published a staff working document setting out the analysis underpinning its proposed Biotech Act, first presented in...
The European Association of Medical Devices Notified Bodies (Team-NB) has published a legal expert opinion concluding that proposed Article 50 of the...
The European Commission has adopted a Global Health Resilience Initiative, setting out a strategic framework for future EU action to enable faster...
STOP PRESS: The Tobacco and Vapes Act 2026 received Royal Assent on 29 April 2026 and partly entered into force on that date. The TVA is discussed in...
What is a technology transfer agreement?The term ‘technology transfer agreement’ is used as an umbrella term for a multitude of different types of...
Grounds of patent invalidity and revocationA patent may be revoked if it is held to be invalid on one or more grounds. Revocation has retrospective...
This Practice Note tracks and summarises EU regulatory legislation guidance and other ongoing policy developments in the agriculture and food sector....
The UK’s formal withdrawal from the EU took effect at 11 pm on 31 January 2020 (exit day). At this point, the withdrawal period under Article 50 TEU...
These training materials consist of template PowerPoint slides that can be used as the basis of one or more training seminars on the United Kingdom...
These Precedent sustainability definitions, produced by The Chancery Lane Project (TCLP) as part of its climate change glossary, provide definitions...
1Appointment and powersWe, [insert name of company] a company incorporated in [England and Wales] under number [insert registered number] whose...
The Directors[Insert name of company][(Company)][Insert address][Insert date]Dear [Directors],General notification of interest in an existing...
1Declaration of interests1.1[The Chair drew the attention of the Meeting to:1.1.1[a declaration of interest by notice in writing from [insert name of...
Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...
Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...
Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
An organisation that has been appointed by the authorities'>competent authorities of a Member State to conduct conformity assessment procedures in respect of medical devices and verify the conformity of the manufacturer with the requirements of the medical devices legislation. The Notified Bodies are listed on the Commission website.
Refers to the data exclusivity period granted by Article 10(1) of Directive 2001/83/EC, in which pre-clinical and clinical trial data generated and used to support the authorisation of an innovative medicinal product cannot be referred to by an applicant for a marketing authorisation for a generic product.
Unlicensed medicinal products for human use which have been specially manufactured or imported to the order of a doctor, dentist, nurse independent prescriber, pharmacist independent prescriber or supplementary prescriber for the treatment of individual patients in order to fulfil the special needs of an individual patient.